1 / 9

Pricing and Reimbursement

Pricing and Reimbursement. Policies. 27. Pricing Policies Patented Medicines • Patented Medicine Prices Review Board (PMPRB) monitors and sets the price of patented medicines • Judges whether a price is “excessive” for new patented drugs and existing patented drugs

eli
Download Presentation

Pricing and Reimbursement

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PricingandReimbursement Policies 27

  2. PricingPoliciesPatentedMedicines •PatentedMedicinePricesReviewBoard(PMPRB)monitorsand setsthepriceofpatentedmedicines •Judgeswhetherapriceis“excessive”fornewpatenteddrugs andexistingpatenteddrugs •PMPRBregulationsmandatedandguidedbys79-103the PatentAct •PMPRBuses2stepprocesstosetandreviewpricesfornew patenteddrugproducts: 1. 2. Scientificreview Pricereview 28

  3. ScientificReview •Thepurposeofthescientificreviewprocessistoestablish: “leveloftherapeuticimprovementofapatenteddrugproduct” •LeveloftherapeuticimprovementassessedbyHumanDrug AdvisoryPanel •Fourcategoriesoftherapeuticimprovement: 1. 2. 3. 4. Breakthrough SubstantialImprovement ModerateImprovement SlightorNoImprovement 29

  4. PriceReviewProcess •Leveloftherapeuticimprovementusedtodetermineifapriceis “excessive” 1. 2. 3. 4. Breakthrough:excessivepricedeterminedbyinternational referencepricing(IRP);France,Germany,Italy,Sweden, Switzerland,theUnitedKingdom,andtheUnitedStates SubstantialImprovement:priceisexcessiveifhigherofIRPprice ORhighestnon-excessivepricecomparedwithdrugsin therapeuticclass(TCCtest) ModerateImprovement:IRPand/orTCC SlightorNoImprovement:TCCorIRP 30

  5. PMPRBInvestigationsandHearings •PMPRBcaninitiateinvestigationsintoexcessivepricing •Ifexcessivepricingisdetermined,investigatedpartycanagree toalowerpriceandoffsetanyrevenuebasedonexcessive pricing(VoluntaryComplianceUndertaking) •Ifinvestigatedpartydoesnotagreetolowerpricevoluntarily PMPRBcanholdhearingsandultimatelyorderpricetobe loweredanddoublerevenueamountstobeoffset •Hearingdecisionsaresubjecttofederaljudicialreview 31

  6. ReimbursementPolicies •Prescriptiondrugscoveredthroughprivateand provincial/territorialpublicplans •Covers98%ofpopulation •Federalgovernmentonlyprovidescoverageforasmallnumber ofindividuals,circa.1million •Plansvaryinscope,coverageandreimbursementpoliciesfrom province/territorytoprovince/territory 32

  7. GenericSubstitutionandPricing Substitution •Interchangeabilityandsubstitutionrulessetatprovinciallevel •Substitutionrulesdifferfromprovincetoprovince •Biggestprovinces–includingOntario,BCandQuebec–allow, butdo notmandategenericsubstitution •Saskatchewan,Manitoba,PEI,NewfoundlandandLabrador mandatesubstitution Pricing •Highgenericpriceshaveresultedinprovincialpricecaps: i. ii. Ontario:pricescappedat25-35%ofbrandlistprice Quebec:cappedathighestprovincialpricee.g.Ontario iii.Alberta:pricescappedat45-56%ofbrandlistprice iv.BritishColumbia:pricescappedat35-42%ofbrandlist price 33

  8. FederalHTA •CanadianAgencyforDrugsandTechnologiesinHealth (CADTH)conducts“clinical,cost-effectiveness,andpatient evidence”assessmentsforpublicsectorhealthcaredecision makers •CommonDrugReview(CDR): –reviewofDrugSubmissionsfrompublicbodies –providesformularylistingrecommendationstoallCanadianpublicly fundedfederal,provincial,andterritorialdrugplansexceptQuebec. •Only50%ofdrugsthatundergoCDRrecommendedfor reimbursement •Finaldecisionrestswithprovinces/territories–CDRmakes recommendationdoesnotmandateformularylistings 34

  9. Provincial/TerritorialHTA •ProvincesandterritorieshaveownHTAbodies •Quebec:Agenced’ÉvaluationdesTechnologiesetdesModes d’InterventionenSanté •Ontario:MedicalAdvisorySecretariat(MAS) •Alberta:InstituteofHealthEconomics •Provincial/territorialrecommendationsarealsonon-binding 35

More Related